Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 556 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Mom Who Lost Child Donates Breast Milk To Mom With Cancer February 27, 2019 FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T... August 12, 2026 At 27, She Was Told She Was Too Young For Breast... February 6, 2020 Introducing our new podcast for researchers February 4, 2022 Load more HOT NEWS “Supporting research is mission critical for me and always will be”... Meet Rosalie: St. Jude Children’s Research Hospital’s New Service Dog For... Coming Soon: Medicare Drug Price Negotiations Researchers Have Harnessed a Compound from a Common Plant Called Feverfew...
